Kairasec Tafla 32 mg 冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

kairasec tafla 32 mg

medical valley invest ab - candesartanum cílexetíl - tafla - 32 mg

Letrozol Actavis Filmuhúðuð tafla 2,5 mg 冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

letrozol actavis filmuhúðuð tafla 2,5 mg

actavis group ptc ehf. - letrozolum inn - filmuhúðuð tafla - 2,5 mg

Letrozole Bluefish Filmuhúðuð tafla 2,5 mg 冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

letrozole bluefish filmuhúðuð tafla 2,5 mg

bluefish pharmaceuticals ab - letrozolum inn - filmuhúðuð tafla - 2,5 mg

Tyruko 欧盟 - 冰岛文 - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalízúmab - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ónæmisbælandi lyf - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.